Statement: There were no adverse event in the primary trial which occurred more than 71 times.
Primary_evidence: Adverse Events 1:   Total: 10/71 (14.08%)   ATRIAL FIBRILLATION 1/71 (1.41%)   CARDIAC TAMPONADE 1/71 (1.41%)   PERICARDIAL EFFUSION 1/71 (1.41%)   SUPRAVENTRICULAR TACHYCARDIA 1/71 (1.41%)   DIARRHOEA 1/71 (1.41%)   NAUSEA 1/71 (1.41%)   VOMITING 1/71 (1.41%)   CHEST PAIN 1/71 (1.41%)   PNEUMONIA 1/71 (1.41%)   MALIGNANT PLEURAL EFFUSION 1/71 (1.41%)   HEPATIC ENCEPHALOPATHY 1/71 (1.41%)